Dry amorphisation of mangiferin, a poorly water-soluble compound, using mesoporous silica
[Display omitted] Mangiferin, a poorly water soluble compound, was processed via a dry amorphisation technique (ball milling) in combination with mesoporous silica to enhance the solubility of mangiferin. The amorphous samples were prepared by mixing 1:1 (w/w) Syloid® XDP 3050 silica-mangiferin mixt...
Saved in:
Published in | European journal of pharmaceutics and biopharmaceutics Vol. 141; pp. 172 - 179 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
Elsevier B.V
01.08.2019
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | [Display omitted]
Mangiferin, a poorly water soluble compound, was processed via a dry amorphisation technique (ball milling) in combination with mesoporous silica to enhance the solubility of mangiferin.
The amorphous samples were prepared by mixing 1:1 (w/w) Syloid® XDP 3050 silica-mangiferin mixtures using a planetary mono mill at different milling speeds and milling times according to a 32 full factorial experimental design. The prepared samples were characterized for dissolution profile, particle size distribution using laser diffraction particle size analyzer, thermal characteristics using DSC, crystalline characteristics using XRD and molecular interactions using FTIR and ss-NMR. The samples were tested for stability at stress conditions (40 °C/75%RH) for up to 6 months in open and closed containers. To improve stability of the samples, mixtures of 1:1:2 mangiferin-polymer (Soluplus or HPMC)-silica samples were also prepared and analyzed.
Amorphisation of mangiferin is possible using dry amorphisation by ball milling with mesoporous silica in a short amount of time. The amorphisation rate of the samples improved with the energy input of the milling process. The samples prepared with high energy input resulted in amorphous samples and showed a better stability at the stress conditions for up to 3 months. Solubility of these samples increased from 0.32 to 0.50 mg/ml and the particle size decreased from 35.5 µm to around 7 µm. The spectral analysis suggest presence of interactions between the silica material and the compound. The amorphous stability was improved with addition of polymer, even though the solubility of the samples was lower. |
---|---|
AbstractList | Mangiferin, a poorly water soluble compound, was processed via a dry amorphisation technique (ball milling) in combination with mesoporous silica to enhance the solubility of mangiferin. The amorphous samples were prepared by mixing 1:1 (w/w) Syloid® XDP 3050 silica-mangiferin mixtures using a planetary mono mill at different milling speeds and milling times according to a 3
full factorial experimental design. The prepared samples were characterized for dissolution profile, particle size distribution using laser diffraction particle size analyzer, thermal characteristics using DSC, crystalline characteristics using XRD and molecular interactions using FTIR and ss-NMR. The samples were tested for stability at stress conditions (40 °C/75%RH) for up to 6 months in open and closed containers. To improve stability of the samples, mixtures of 1:1:2 mangiferin-polymer (Soluplus or HPMC)-silica samples were also prepared and analyzed. Amorphisation of mangiferin is possible using dry amorphisation by ball milling with mesoporous silica in a short amount of time. The amorphisation rate of the samples improved with the energy input of the milling process. The samples prepared with high energy input resulted in amorphous samples and showed a better stability at the stress conditions for up to 3 months. Solubility of these samples increased from 0.32 to 0.50 mg/ml and the particle size decreased from 35.5 µm to around 7 µm. The spectral analysis suggest presence of interactions between the silica material and the compound. The amorphous stability was improved with addition of polymer, even though the solubility of the samples was lower. [Display omitted] Mangiferin, a poorly water soluble compound, was processed via a dry amorphisation technique (ball milling) in combination with mesoporous silica to enhance the solubility of mangiferin. The amorphous samples were prepared by mixing 1:1 (w/w) Syloid® XDP 3050 silica-mangiferin mixtures using a planetary mono mill at different milling speeds and milling times according to a 32 full factorial experimental design. The prepared samples were characterized for dissolution profile, particle size distribution using laser diffraction particle size analyzer, thermal characteristics using DSC, crystalline characteristics using XRD and molecular interactions using FTIR and ss-NMR. The samples were tested for stability at stress conditions (40 °C/75%RH) for up to 6 months in open and closed containers. To improve stability of the samples, mixtures of 1:1:2 mangiferin-polymer (Soluplus or HPMC)-silica samples were also prepared and analyzed. Amorphisation of mangiferin is possible using dry amorphisation by ball milling with mesoporous silica in a short amount of time. The amorphisation rate of the samples improved with the energy input of the milling process. The samples prepared with high energy input resulted in amorphous samples and showed a better stability at the stress conditions for up to 3 months. Solubility of these samples increased from 0.32 to 0.50 mg/ml and the particle size decreased from 35.5 µm to around 7 µm. The spectral analysis suggest presence of interactions between the silica material and the compound. The amorphous stability was improved with addition of polymer, even though the solubility of the samples was lower. |
Author | Adriaensens, Peter Kiekens, Filip Lammens, Joris Delgado Hernandez, René Vervaet, Chris Baán, Adrienn Pieters, Luc Vanden Berghe, Wim |
Author_xml | – sequence: 1 givenname: Adrienn surname: Baán fullname: Baán, Adrienn email: adrienn.baan@uantwerpen.be organization: University of Antwerp, Department of Pharmaceutical Technology and Biopharmacy, Universiteitsplein 1 2610 Wilrijk, Belgium – sequence: 2 givenname: Peter surname: Adriaensens fullname: Adriaensens, Peter email: peter.adriaensens@uhasselt.be organization: University of Hasselt, Institute for Materials Research, Agoralaan Building D, 3590 Diepenbeek, Belgium – sequence: 3 givenname: Joris surname: Lammens fullname: Lammens, Joris organization: Ghent University, Laboratory of Pharmaceutical Technology, Ottergemsesteenweg 460, 9000 Ghent, Belgium – sequence: 4 givenname: René surname: Delgado Hernandez fullname: Delgado Hernandez, René email: rene.delgado@cidem.sld.cu organization: Universidad de la Habana, Instituto de Farmacia y Alimentos, 222 La Habana, Cuba – sequence: 5 givenname: Wim surname: Vanden Berghe fullname: Vanden Berghe, Wim email: wim.vandenberghe@uantwerpen.be organization: University of Antwerp, Department of Biomedical Sciences, Universiteitsplein 1 2610 Wilrijk, Belgium – sequence: 6 givenname: Luc surname: Pieters fullname: Pieters, Luc email: luc.pieters@uantwerpen.be organization: University of Antwerp, Department of Pharmaceutical Sciences, Universiteitsplein 1 2610 Wilrijk, Belgium – sequence: 7 givenname: Chris surname: Vervaet fullname: Vervaet, Chris email: chris.vervaet@ugent.be organization: Ghent University, Laboratory of Pharmaceutical Technology, Ottergemsesteenweg 460, 9000 Ghent, Belgium – sequence: 8 givenname: Filip surname: Kiekens fullname: Kiekens, Filip email: filip.kiekens@uantwerpen.be organization: University of Antwerp, Department of Pharmaceutical Technology and Biopharmacy, Universiteitsplein 1 2610 Wilrijk, Belgium |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31150810$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kMtOwzAURC1URB_wAyyQP6AJ98aJ20hsUHlKldjAgpXlOHZxlMSRnYD696QqsGQ1mzmj0ZmTSetaTcglQoyA_LqKddUVcQKYx5DFkPATMsP1ikUsTXFCZpCzPOIp4pTMQ6gAIF1l6zMyZYgZrBFm5P3O76lsnO8-bJC9dS11hjay3VmjvW2XVNLOOV_v6ZfstY-Cq4ei1lS5pnNDWy7pEGy7o40OrnPeDYEGW1slz8mpkXXQFz-5IG8P96-bp2j78vi8ud1GKgXoIwSueGJ4iQyTQuYZH9PIRPJSMVipFZpUyiTjRqcSGeQqKbICTFEyydka2YIkx13lXQheG9F520i_Fwji4ElU4uBJHDwJyMToaYSujlA3FI0u_5BfMWPh5ljQ4_VPq70IyupW6dJ6rXpROvvf_jdiz3xJ |
CitedBy_id | crossref_primary_10_1016_j_ejps_2021_106015 crossref_primary_10_2174_1567201819666220721111852 crossref_primary_10_1016_j_ejpb_2021_04_004 crossref_primary_10_3390_molecules28155918 crossref_primary_10_1016_j_ijpharm_2023_122717 crossref_primary_10_1016_j_ejpb_2022_08_010 crossref_primary_10_1016_j_ijbiomac_2021_01_001 crossref_primary_10_3389_fphar_2021_670167 crossref_primary_10_5802_crchim_82 crossref_primary_10_3390_molecules28083406 crossref_primary_10_1016_j_jddst_2020_101733 crossref_primary_10_1016_j_jddst_2024_105698 crossref_primary_10_1021_acs_molpharmaceut_0c00811 crossref_primary_10_1080_10408398_2021_1983767 |
Cites_doi | 10.1351/pac198557040603 10.1016/j.powtec.2019.02.010 10.1039/b707322d 10.1016/j.addr.2007.05.012 10.1016/j.ssc.2006.02.007 10.1007/s11095-013-1075-7 10.1016/j.jddst.2015.01.002 10.1016/j.jsps.2013.05.004 10.1517/17425247.2.1.335 10.1080/10717540601098823 10.1016/j.addr.2007.05.010 10.1007/978-1-4939-1598-9_23 10.1007/s11095-006-9062-x 10.1002/biof.1292 10.1016/j.ejpb.2011.08.005 10.1016/j.ajps.2014.12.006 10.1002/jps.23678 10.1186/s12944-017-0449-y 10.1016/j.ijpharm.2017.03.078 10.1070/RC2006v075n03ABEH001205 10.1002/jps.23966 10.1016/j.ejpb.2012.02.004 10.1016/j.canlet.2011.02.011 10.1080/10837450802012869 10.1007/s10847-008-9456-y |
ContentType | Journal Article |
Copyright | 2019 Elsevier B.V. Copyright © 2019. Published by Elsevier B.V. |
Copyright_xml | – notice: 2019 Elsevier B.V. – notice: Copyright © 2019. Published by Elsevier B.V. |
DBID | NPM AAYXX CITATION |
DOI | 10.1016/j.ejpb.2019.05.026 |
DatabaseName | PubMed CrossRef |
DatabaseTitle | PubMed CrossRef |
DatabaseTitleList | PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1873-3441 |
EndPage | 179 |
ExternalDocumentID | 10_1016_j_ejpb_2019_05_026 31150810 S0939641119302619 |
Genre | Journal Article |
GroupedDBID | --- --K --M .~1 0R~ 1B1 1RT 1~. 1~5 29G 4.4 457 4G. 53G 5GY 5VS 7-5 71M 8P~ AABNK AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATCM AAXUO AAYOK ABFNM ABFRF ABGSF ABJNI ABMAC ABUDA ABXDB ABYKQ ABZDS ACDAQ ACGFO ACIUM ACRLP ADBBV ADEZE ADMUD ADUVX AEBSH AEFWE AEHWI AEKER AENEX AFKWA AFTJW AFXIZ AGHFR AGRDE AGUBO AGYEJ AIEXJ AIKHN AITUG AJBFU AJOXV ALCLG ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC C45 CS3 DOVZS DU5 EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 FDB FEDTE FGOYB FIRID FNPLU FYGXN G-Q GBLVA HVGLF HZ~ IHE J1W KOM M41 MO0 N9A O-L O9- OAUVE OGGZJ OVD OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SDF SDG SES SEW SPCBC SSP SSU SSZ T5K TEORI UNMZH ~G- AAXKI AKRWK NPM AAYXX AFJKZ CITATION |
ID | FETCH-LOGICAL-c400t-106c62f6d1312ba956312fa2a6dc307c71f4aa256fe4a1309c2b5b0fbd3a63813 |
IEDL.DBID | AIKHN |
ISSN | 0939-6411 |
IngestDate | Thu Sep 26 17:04:27 EDT 2024 Wed Oct 16 00:51:49 EDT 2024 Fri Feb 23 02:36:42 EST 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | Solubility improvement Solid dispersions Drug formulation Dry amorphisation Mesoporous silica Co-milling |
Language | English |
License | Copyright © 2019. Published by Elsevier B.V. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c400t-106c62f6d1312ba956312fa2a6dc307c71f4aa256fe4a1309c2b5b0fbd3a63813 |
OpenAccessLink | https://repository.uantwerpen.be/docman/irua/d1e2f8/159943.2020_05_30 |
PMID | 31150810 |
PageCount | 8 |
ParticipantIDs | crossref_primary_10_1016_j_ejpb_2019_05_026 pubmed_primary_31150810 elsevier_sciencedirect_doi_10_1016_j_ejpb_2019_05_026 |
PublicationCentury | 2000 |
PublicationDate | 2019-08-01 |
PublicationDateYYYYMMDD | 2019-08-01 |
PublicationDate_xml | – month: 08 year: 2019 text: 2019-08-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Netherlands |
PublicationPlace_xml | – name: Netherlands |
PublicationTitle | European journal of pharmaceutics and biopharmaceutics |
PublicationTitleAlternate | Eur J Pharm Biopharm |
PublicationYear | 2019 |
Publisher | Elsevier B.V |
Publisher_xml | – name: Elsevier B.V |
References | García-Rivera, Delgado, Bougarne, Haegeman, Vanden Berghe (b0110) 2011; 305 Maggi, Canobbio, Bruni, Musitelli, Conte (b0090) 2015; 26 Paudel, Geppi, Van Den Mooter (b0025) 2014; 103 Loh, Samanta, Sia Heng (b0155) 2014; 10 Brewster, Loftsson (b0040) 2007; 59 ICH Harmonized Tripartite Guideline: Stability testing of New Drug Substances and Products Q1A (R2), in: Int. Conf. Harmon. Tech. Requir. Regist. Pharm. Hum. Use, 2003. Sing, Everett, Haul, Moscou, Pierotti, Rouquérol, Siemieniewska (b0060) 1985; 57 Limnell, Heikkilä, Santos, Sistonen, Hellstén, Laaksonen, Peltonen, Kumar, Murzin, Louhi-Kultanen, Salonen, Hirvonen, Lehto (b0070) 2011; 416 Löbmann, Strachan, Grohganz, Rades, Korhonen, Laitinen (b0085) 2012; 81 Boldyrev (b0160) 2006; 75 Bahl, Bogner (b0100) 2006; 23 Heikkilä, Salonen, Tuura, Kumar, Salmi, Murzin, Hamdy, Mul, Laitinen, Kaukonen, Hirvonen, Lehto (b0075) 2007; 14 Branham, Moyo, Govender (b0150) 2012; 80 Buntkowsky, Breitzke, Adamczyk, Roelofs, Emmler, Gedat, Grünberg, Xu, Limbach, Shenderovich, Vyalikh, Findenegg (b0165) 2007; 9 Dudognon, Willart, Caron, Capet, Larsson, Descamps (b0080) 2006; 138 Douroumis, Fahr (b0050) 2013 Imran, Arshad, Butt, Kwon, Arshad, Sultan (b0115) 2017; 16 Serajuddin (b0010) 2007; 59 Moore, Flanner (b0130) 1996; 20 Lieberman, Vemuri (b0015) 2015 Sandler, Genina, Wisaeus, Rantanen, Raijada, Peltonen, Fors (b0135) 2013; 102 Vyas, Saraf, Saraf (b0045) 2008; 62 Loftsson, Jarho, Másson, Järvinen, Publications (b0035) 2005; 2 Liu, Tong, He, Wang, Lei, Du, Xie, Wang (b0105) 2018 Bahl, Hudak, Bogner (b0095) 2008; 13 Szafraniec, Antosik, Knapik-Kowalczuk, Kurek, Syrek, Chmiel, Paluch, Jachowicz (b0140) 2017; 533 Vandana, Prasanna Raju, Harini Chowdary, Sushma, Vijay Kumar (b0030) 2014; 22 Vogt, Roberts-Skilton, Kennedy-Gabb (b0065) 2013; 30 Choudhari, Hoefer, Libanati, Monsuur, Mccarthy (b0055) 2014 Jain (b0005) 2014 Saha, Sadhukhan, Sil, Mangiferin (b0120) 2016; 42 Bikiaris (b0020) 2014 Nowak, Krupa, Kubat, Węgrzyn, Harańczyk, Ciułkowska, Jachowicz (b0145) 2019; 346 Moore (10.1016/j.ejpb.2019.05.026_b0130) 1996; 20 Bahl (10.1016/j.ejpb.2019.05.026_b0100) 2006; 23 Limnell (10.1016/j.ejpb.2019.05.026_b0070) 2011; 416 Saha (10.1016/j.ejpb.2019.05.026_b0120) 2016; 42 Lieberman (10.1016/j.ejpb.2019.05.026_b0015) 2015 Serajuddin (10.1016/j.ejpb.2019.05.026_b0010) 2007; 59 10.1016/j.ejpb.2019.05.026_b0125 Buntkowsky (10.1016/j.ejpb.2019.05.026_b0165) 2007; 9 Bahl (10.1016/j.ejpb.2019.05.026_b0095) 2008; 13 Szafraniec (10.1016/j.ejpb.2019.05.026_b0140) 2017; 533 Dudognon (10.1016/j.ejpb.2019.05.026_b0080) 2006; 138 Choudhari (10.1016/j.ejpb.2019.05.026_b0055) 2014 Löbmann (10.1016/j.ejpb.2019.05.026_b0085) 2012; 81 Boldyrev (10.1016/j.ejpb.2019.05.026_b0160) 2006; 75 García-Rivera (10.1016/j.ejpb.2019.05.026_b0110) 2011; 305 Liu (10.1016/j.ejpb.2019.05.026_b0105) 2018 Vogt (10.1016/j.ejpb.2019.05.026_b0065) 2013; 30 Sandler (10.1016/j.ejpb.2019.05.026_b0135) 2013; 102 Douroumis (10.1016/j.ejpb.2019.05.026_b0050) 2013 Jain (10.1016/j.ejpb.2019.05.026_b0005) 2014 Maggi (10.1016/j.ejpb.2019.05.026_b0090) 2015; 26 Vandana (10.1016/j.ejpb.2019.05.026_b0030) 2014; 22 Heikkilä (10.1016/j.ejpb.2019.05.026_b0075) 2007; 14 Vyas (10.1016/j.ejpb.2019.05.026_b0045) 2008; 62 Paudel (10.1016/j.ejpb.2019.05.026_b0025) 2014; 103 Nowak (10.1016/j.ejpb.2019.05.026_b0145) 2019; 346 Imran (10.1016/j.ejpb.2019.05.026_b0115) 2017; 16 Loh (10.1016/j.ejpb.2019.05.026_b0155) 2014; 10 Brewster (10.1016/j.ejpb.2019.05.026_b0040) 2007; 59 Bikiaris (10.1016/j.ejpb.2019.05.026_b0020) 2014 Loftsson (10.1016/j.ejpb.2019.05.026_b0035) 2005; 2 Branham (10.1016/j.ejpb.2019.05.026_b0150) 2012; 80 Sing (10.1016/j.ejpb.2019.05.026_b0060) 1985; 57 |
References_xml | – volume: 16 start-page: 1 year: 2017 end-page: 17 ident: b0115 article-title: Mangiferin: a natural miracle bioactive compound against lifestyle related disorders publication-title: Lipids Health Dis. contributor: fullname: Sultan – volume: 305 start-page: 21 year: 2011 end-page: 31 ident: b0110 article-title: Gallic acid indanone and mangiferin xanthone are strong determinants of immunosuppressive anti-tumour effects of Mangifera indica L. bark in MDA-MB231 breast cancer cells publication-title: Cancer Lett. contributor: fullname: Vanden Berghe – volume: 62 start-page: 23 year: 2008 end-page: 42 ident: b0045 article-title: Cyclodextrin based novel drug delivery systems publication-title: J. Incl. Phenom. Macrocycl. Chem. contributor: fullname: Saraf – volume: 346 start-page: 373 year: 2019 end-page: 384 ident: b0145 article-title: Water vapour sorption in tadalafil-Soluplus co-milled amorphous solid dispersions publication-title: Powder Technol. contributor: fullname: Jachowicz – start-page: 665 year: 2014 end-page: 693 ident: b0055 article-title: Mesoporous silica drug delivery systems publication-title: Amorph. Solid Dispersions. contributor: fullname: Mccarthy – year: 2013 ident: b0050 article-title: Drug delivery strategies for poorly water-soluble drugs contributor: fullname: Fahr – volume: 26 start-page: 17 year: 2015 end-page: 23 ident: b0090 article-title: Improvement of the dissolution behavior of gliclazide, a slightly soluble drug, using solid dispersions publication-title: J. Drug Deliv. Sci. Technol. contributor: fullname: Conte – volume: 13 start-page: 255 year: 2008 end-page: 269 ident: b0095 article-title: Comparison of the ability of various pharmaceutical silicates to amorphize and enhance dissolution of indomethacin upon co-grinding publication-title: Pharm. Dev. Technol. contributor: fullname: Bogner – volume: 138 start-page: 68 year: 2006 end-page: 71 ident: b0080 article-title: Formation of budesonide/α-lactose glass solutions by ball-milling publication-title: Solid State Commun. contributor: fullname: Descamps – volume: 533 start-page: 470 year: 2017 end-page: 479 ident: b0140 article-title: Planetary ball milling and supercritical fluid technology as a way to enhance dissolution of bicalutamide publication-title: Int. J. Pharm. contributor: fullname: Jachowicz – volume: 23 start-page: 2317 year: 2006 end-page: 2325 ident: b0100 article-title: Amorphization of indomethacin by Co-grinding with neusilin US2: amorphization kinetics, physical stability and mechanism publication-title: Pharm. Res. contributor: fullname: Bogner – volume: 14 start-page: 337 year: 2007 end-page: 347 ident: b0075 article-title: Evaluation of mesoporous TCPSi, MCM-41, SBA-15, and TUD-1 materials as API carriers for oral drug delivery publication-title: Drug Delivery contributor: fullname: Lehto – year: 2014 ident: b0005 article-title: Current Status and Future Prospects of Drug Delivery Systems contributor: fullname: Jain – volume: 80 start-page: 194 year: 2012 end-page: 202 ident: b0150 article-title: Preparation and solid-state characterization of ball milled saquinavir mesylate for solubility enhancement publication-title: Eur. J. Pharm. Biopharm. contributor: fullname: Govender – volume: 2 start-page: 329 year: 2005 end-page: 357 ident: b0035 article-title: Expert opinion on drug delivery cyclodextrins in drug delivery publication-title: Exp. Opin. Drug Deliv. contributor: fullname: Publications – start-page: 4775 year: 2018 end-page: 4786 ident: b0105 article-title: Mangiferin: an effective therapeutic agent against several disorders (Review) publication-title: Mol. Med. Rep. contributor: fullname: Wang – year: 2014 ident: b0020 article-title: Solid dispersions part I: recent evolutions and future opportunities in manufacturing methods for dissolution rate enhancement of poorly water-soluble drugs publication-title: Exp. Opin. Drug Deliv. contributor: fullname: Bikiaris – volume: 20 start-page: 64 year: 1996 end-page: 75 ident: b0130 article-title: Mathematical comparison of dissolution profiles publication-title: Pharm. Technol. contributor: fullname: Flanner – volume: 30 start-page: 2315 year: 2013 end-page: 2331 ident: b0065 article-title: A solid-state NMR study of amorphous ezetimibe dispersions in mesoporous silica publication-title: Pharm. Res. contributor: fullname: Kennedy-Gabb – volume: 416 start-page: 242 year: 2011 end-page: 251 ident: b0070 article-title: Physicochemical stability of high indomethacin payload ordered mesoporous silica MCM-41 and SBA-15 microparticles publication-title: Int. J. Pharm. contributor: fullname: Lehto – volume: 57 start-page: 603 year: 1985 end-page: 619 ident: b0060 article-title: Reporting physisorption data for gas/solid systems with special reference to the determination of surface area and porosity publication-title: Pure Appl. Chem. contributor: fullname: Siemieniewska – volume: 81 start-page: 159 year: 2012 end-page: 169 ident: b0085 article-title: Co-amorphous simvastatin and glipizide combinations show improved physical stability without evidence of intermolecular interactions publication-title: Eur. J. Pharm. Biopharm. contributor: fullname: Laitinen – volume: 10 start-page: 255 year: 2014 end-page: 274 ident: b0155 article-title: Overview of milling techniques for improving the solubility of poorly water-soluble drugs publication-title: Asian J. Pharm. Sci. contributor: fullname: Sia Heng – year: 2015 ident: b0015 article-title: Chemical and Physicochemical Approaches to Solve Formulation Problems contributor: fullname: Vemuri – volume: 75 start-page: 177 year: 2006 end-page: 189 ident: b0160 article-title: Mechanochemistry and mechanical activation of solids publication-title: Russ. Chem. Rev. contributor: fullname: Boldyrev – volume: 22 start-page: 283 year: 2014 end-page: 289 ident: b0030 article-title: An overview on in situ micronization technique – an emerging novel concept in advanced drug delivery publication-title: Saudi Pharm. J. contributor: fullname: Vijay Kumar – volume: 59 start-page: 645 year: 2007 end-page: 666 ident: b0040 article-title: Cyclodextrins as pharmaceutical solubilizers publication-title: Adv. Drug Deliv. Rev. contributor: fullname: Loftsson – volume: 59 start-page: 603 year: 2007 end-page: 616 ident: b0010 article-title: Salt formation to improve drug solubility publication-title: Adv. Drug Deliv. Rev. contributor: fullname: Serajuddin – volume: 103 start-page: 2635 year: 2014 end-page: 2662 ident: b0025 article-title: Structural and dynamic properties of amorphous solid dispersions: the role of solid-state nuclear magnetic resonance spectroscopy and relaxometry publication-title: J. Pharm. Sci. contributor: fullname: Van Den Mooter – volume: 102 start-page: 3694 year: 2013 end-page: 3704 ident: b0135 article-title: A step toward development of printable dosage forms for poorly soluble drugs publication-title: J. Pharm. Sci. contributor: fullname: Fors – volume: 9 start-page: 4843 year: 2007 end-page: 4853 ident: b0165 article-title: Structural and dynamical properties of guest molecules confined in mesoporous silica materials revealed by NMR publication-title: Phys. Chem. Chem. Phys. contributor: fullname: Findenegg – volume: 42 start-page: 459 year: 2016 end-page: 474 ident: b0120 article-title: A xanthonoid with multipotent anti-inflammatory potential publication-title: BioFactors contributor: fullname: Mangiferin – volume: 57 start-page: 603 year: 1985 ident: 10.1016/j.ejpb.2019.05.026_b0060 article-title: Reporting physisorption data for gas/solid systems with special reference to the determination of surface area and porosity publication-title: Pure Appl. Chem. doi: 10.1351/pac198557040603 contributor: fullname: Sing – volume: 346 start-page: 373 year: 2019 ident: 10.1016/j.ejpb.2019.05.026_b0145 article-title: Water vapour sorption in tadalafil-Soluplus co-milled amorphous solid dispersions publication-title: Powder Technol. doi: 10.1016/j.powtec.2019.02.010 contributor: fullname: Nowak – volume: 9 start-page: 4843 year: 2007 ident: 10.1016/j.ejpb.2019.05.026_b0165 article-title: Structural and dynamical properties of guest molecules confined in mesoporous silica materials revealed by NMR publication-title: Phys. Chem. Chem. Phys. doi: 10.1039/b707322d contributor: fullname: Buntkowsky – volume: 59 start-page: 645 year: 2007 ident: 10.1016/j.ejpb.2019.05.026_b0040 article-title: Cyclodextrins as pharmaceutical solubilizers publication-title: Adv. Drug Deliv. Rev. doi: 10.1016/j.addr.2007.05.012 contributor: fullname: Brewster – volume: 138 start-page: 68 year: 2006 ident: 10.1016/j.ejpb.2019.05.026_b0080 article-title: Formation of budesonide/α-lactose glass solutions by ball-milling publication-title: Solid State Commun. doi: 10.1016/j.ssc.2006.02.007 contributor: fullname: Dudognon – volume: 30 start-page: 2315 year: 2013 ident: 10.1016/j.ejpb.2019.05.026_b0065 article-title: A solid-state NMR study of amorphous ezetimibe dispersions in mesoporous silica publication-title: Pharm. Res. doi: 10.1007/s11095-013-1075-7 contributor: fullname: Vogt – volume: 26 start-page: 17 year: 2015 ident: 10.1016/j.ejpb.2019.05.026_b0090 article-title: Improvement of the dissolution behavior of gliclazide, a slightly soluble drug, using solid dispersions publication-title: J. Drug Deliv. Sci. Technol. doi: 10.1016/j.jddst.2015.01.002 contributor: fullname: Maggi – volume: 22 start-page: 283 year: 2014 ident: 10.1016/j.ejpb.2019.05.026_b0030 article-title: An overview on in situ micronization technique – an emerging novel concept in advanced drug delivery publication-title: Saudi Pharm. J. doi: 10.1016/j.jsps.2013.05.004 contributor: fullname: Vandana – volume: 2 start-page: 329 year: 2005 ident: 10.1016/j.ejpb.2019.05.026_b0035 article-title: Expert opinion on drug delivery cyclodextrins in drug delivery publication-title: Exp. Opin. Drug Deliv. doi: 10.1517/17425247.2.1.335 contributor: fullname: Loftsson – start-page: 4775 year: 2018 ident: 10.1016/j.ejpb.2019.05.026_b0105 article-title: Mangiferin: an effective therapeutic agent against several disorders (Review) publication-title: Mol. Med. Rep. contributor: fullname: Liu – year: 2015 ident: 10.1016/j.ejpb.2019.05.026_b0015 contributor: fullname: Lieberman – volume: 14 start-page: 337 issue: 6 year: 2007 ident: 10.1016/j.ejpb.2019.05.026_b0075 article-title: Evaluation of mesoporous TCPSi, MCM-41, SBA-15, and TUD-1 materials as API carriers for oral drug delivery publication-title: Drug Delivery doi: 10.1080/10717540601098823 contributor: fullname: Heikkilä – volume: 59 start-page: 603 year: 2007 ident: 10.1016/j.ejpb.2019.05.026_b0010 article-title: Salt formation to improve drug solubility publication-title: Adv. Drug Deliv. Rev. doi: 10.1016/j.addr.2007.05.010 contributor: fullname: Serajuddin – start-page: 665 year: 2014 ident: 10.1016/j.ejpb.2019.05.026_b0055 article-title: Mesoporous silica drug delivery systems publication-title: Amorph. Solid Dispersions. doi: 10.1007/978-1-4939-1598-9_23 contributor: fullname: Choudhari – year: 2014 ident: 10.1016/j.ejpb.2019.05.026_b0005 contributor: fullname: Jain – volume: 23 start-page: 2317 year: 2006 ident: 10.1016/j.ejpb.2019.05.026_b0100 article-title: Amorphization of indomethacin by Co-grinding with neusilin US2: amorphization kinetics, physical stability and mechanism publication-title: Pharm. Res. doi: 10.1007/s11095-006-9062-x contributor: fullname: Bahl – volume: 20 start-page: 64 year: 1996 ident: 10.1016/j.ejpb.2019.05.026_b0130 article-title: Mathematical comparison of dissolution profiles publication-title: Pharm. Technol. contributor: fullname: Moore – volume: 42 start-page: 459 year: 2016 ident: 10.1016/j.ejpb.2019.05.026_b0120 article-title: A xanthonoid with multipotent anti-inflammatory potential publication-title: BioFactors doi: 10.1002/biof.1292 contributor: fullname: Saha – volume: 416 start-page: 242 year: 2011 ident: 10.1016/j.ejpb.2019.05.026_b0070 article-title: Physicochemical stability of high indomethacin payload ordered mesoporous silica MCM-41 and SBA-15 microparticles publication-title: Int. J. Pharm. contributor: fullname: Limnell – year: 2014 ident: 10.1016/j.ejpb.2019.05.026_b0020 article-title: Solid dispersions part I: recent evolutions and future opportunities in manufacturing methods for dissolution rate enhancement of poorly water-soluble drugs publication-title: Exp. Opin. Drug Deliv. contributor: fullname: Bikiaris – volume: 80 start-page: 194 year: 2012 ident: 10.1016/j.ejpb.2019.05.026_b0150 article-title: Preparation and solid-state characterization of ball milled saquinavir mesylate for solubility enhancement publication-title: Eur. J. Pharm. Biopharm. doi: 10.1016/j.ejpb.2011.08.005 contributor: fullname: Branham – volume: 10 start-page: 255 year: 2014 ident: 10.1016/j.ejpb.2019.05.026_b0155 article-title: Overview of milling techniques for improving the solubility of poorly water-soluble drugs publication-title: Asian J. Pharm. Sci. doi: 10.1016/j.ajps.2014.12.006 contributor: fullname: Loh – volume: 102 start-page: 3694 year: 2013 ident: 10.1016/j.ejpb.2019.05.026_b0135 article-title: A step toward development of printable dosage forms for poorly soluble drugs publication-title: J. Pharm. Sci. doi: 10.1002/jps.23678 contributor: fullname: Sandler – volume: 16 start-page: 1 year: 2017 ident: 10.1016/j.ejpb.2019.05.026_b0115 article-title: Mangiferin: a natural miracle bioactive compound against lifestyle related disorders publication-title: Lipids Health Dis. doi: 10.1186/s12944-017-0449-y contributor: fullname: Imran – volume: 533 start-page: 470 year: 2017 ident: 10.1016/j.ejpb.2019.05.026_b0140 article-title: Planetary ball milling and supercritical fluid technology as a way to enhance dissolution of bicalutamide publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2017.03.078 contributor: fullname: Szafraniec – volume: 75 start-page: 177 year: 2006 ident: 10.1016/j.ejpb.2019.05.026_b0160 article-title: Mechanochemistry and mechanical activation of solids publication-title: Russ. Chem. Rev. doi: 10.1070/RC2006v075n03ABEH001205 contributor: fullname: Boldyrev – ident: 10.1016/j.ejpb.2019.05.026_b0125 – volume: 103 start-page: 2635 year: 2014 ident: 10.1016/j.ejpb.2019.05.026_b0025 article-title: Structural and dynamic properties of amorphous solid dispersions: the role of solid-state nuclear magnetic resonance spectroscopy and relaxometry publication-title: J. Pharm. Sci. doi: 10.1002/jps.23966 contributor: fullname: Paudel – volume: 81 start-page: 159 year: 2012 ident: 10.1016/j.ejpb.2019.05.026_b0085 article-title: Co-amorphous simvastatin and glipizide combinations show improved physical stability without evidence of intermolecular interactions publication-title: Eur. J. Pharm. Biopharm. doi: 10.1016/j.ejpb.2012.02.004 contributor: fullname: Löbmann – volume: 305 start-page: 21 year: 2011 ident: 10.1016/j.ejpb.2019.05.026_b0110 article-title: Gallic acid indanone and mangiferin xanthone are strong determinants of immunosuppressive anti-tumour effects of Mangifera indica L. bark in MDA-MB231 breast cancer cells publication-title: Cancer Lett. doi: 10.1016/j.canlet.2011.02.011 contributor: fullname: García-Rivera – volume: 13 start-page: 255 year: 2008 ident: 10.1016/j.ejpb.2019.05.026_b0095 article-title: Comparison of the ability of various pharmaceutical silicates to amorphize and enhance dissolution of indomethacin upon co-grinding publication-title: Pharm. Dev. Technol. doi: 10.1080/10837450802012869 contributor: fullname: Bahl – year: 2013 ident: 10.1016/j.ejpb.2019.05.026_b0050 contributor: fullname: Douroumis – volume: 62 start-page: 23 year: 2008 ident: 10.1016/j.ejpb.2019.05.026_b0045 article-title: Cyclodextrin based novel drug delivery systems publication-title: J. Incl. Phenom. Macrocycl. Chem. doi: 10.1007/s10847-008-9456-y contributor: fullname: Vyas |
SSID | ssj0004758 |
Score | 2.4212 |
Snippet | [Display omitted]
Mangiferin, a poorly water soluble compound, was processed via a dry amorphisation technique (ball milling) in combination with mesoporous... Mangiferin, a poorly water soluble compound, was processed via a dry amorphisation technique (ball milling) in combination with mesoporous silica to enhance... |
SourceID | crossref pubmed elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 172 |
SubjectTerms | Co-milling Drug formulation Dry amorphisation Mesoporous silica Solid dispersions Solubility improvement |
Title | Dry amorphisation of mangiferin, a poorly water-soluble compound, using mesoporous silica |
URI | https://dx.doi.org/10.1016/j.ejpb.2019.05.026 https://www.ncbi.nlm.nih.gov/pubmed/31150810 |
Volume | 141 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8NAEB5qvXgR39YXexAvNrabd46lKlWxFGxBT2GfJWKT0gfSi7_d2SS1eulBCISEbDZ8s_PY8M0MwKWjo9APqbAcqW3L9TxhhUI4VuS5QgXC1jRvB_Tc9TsD9_HVe61Ae5kLY2iVpe0vbHpurcs7jRLNxjhJGi-4F498F3U1cvKNxAZsojuywypsth6eOt1VemSQt-k0z1tmQJk7U9C81PuYG4ZXlBfwNDUW1vqnX87nfge2y6iRtIoP24WKSvfgqleUnV7USX-VRTWtkyvSWxWkXuzD2-1kQdgoQ0hL8g7JNBmxdGh4LUlaJ4yMs2zysSCfGHpOLLMe-Ycihm9u2i7ViaHHD8lITTOM17P5lEwT87fvAAb3d_12xypbKlgClXWGRtcXvq19SR1qc4abIzxrZjNfCtR2EVDtMoZhkFYuQ_cWCZt7vKm5dBhqKnUOoZpmqToGEsrIpk5APcmlGygjcCmFdJt4RD7XNbheAhmPi8oZ8ZJS9h4b2GMDe9z0YoS9Bt4S6_iP_GM07WvHHRWC-ZnDlA_COKd58s83nsKWuSpIfmdQnU3m6hwDjxm_gI2bL3pRLq9vJADX5A |
link.rule.ids | 315,783,787,4509,24128,27936,27937,45597,45691 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1JS8NAFB60HvQi7tZ1DtKLDW32zrGopS4tBVuop2HWErFJ6ILk3_smSa1ePAiBQJLJhG_mvfkmfO89hG5cTVpByxaWK7Vjeb4vrJYQrkV8T6hQONrOywH1-kF35D2N_fEGulvFwhhZZen7C5-ee-vySqNEs5FGUeMV9uIk8MBWiZtvJDbRFrABAta51X587vbX4ZFhXqbTPG-ZBmXsTCHzUu8pNwovkifwNDkW_lyffiw-nT20W7JG3C4-bB9tqPgA1QZF2umsjofrKKp5HdfwYJ2QOjtEb_ezDLNpApCW4h2caDxl8cToWqK4jhlOk2T2keFPoJ4zy8xH_qGw0Zubskt1bOTxEzxV8wT4erKc43lk_vYdoVHnYXjXtcqSCpYAY12A0w1E4OhA2q7tcAabIzhr5rBACrB2EdraYwxokFYeg-WNCIf7vKm5dBlYqu0eo0qcxOoU4ZYkju2Gti-59EJlBlxKIb0mHCTguopuV0DStMicQVeSsndqYKcGdtr0KcBeRf4Ka_pr_Cm49j_bnRQD892HSR8EPKd59s83XqPt7rD3Ql8e-8_naMfcKQR_F6iymC3VJZCQBb8qJ9kXX8bZ2A |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Dry+amorphisation+of+mangiferin%2C+a+poorly+water-soluble+compound%2C+using+mesoporous+silica&rft.jtitle=European+journal+of+pharmaceutics+and+biopharmaceutics&rft.au=Ba%C3%A1n%2C+Adrienn&rft.au=Adriaensens%2C+Peter&rft.au=Lammens%2C+Joris&rft.au=Delgado+Hernandez%2C+Ren%C3%A9&rft.date=2019-08-01&rft.eissn=1873-3441&rft_id=info:doi/10.1016%2Fj.ejpb.2019.05.026&rft_id=info%3Apmid%2F31150810&rft.externalDocID=31150810 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0939-6411&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0939-6411&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0939-6411&client=summon |